Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Lilly, Novo Dip as Proposed Medicare Coverage for GLP-1 Pilot Thrown Off Balance
The Centers for Medicare & Medicaid Services (CMS) has indefinitely postponed its BALANCE financing model, a pilot intended to expand Medicare coverage for GLP‑1 obesity drugs. The delay triggered a roughly 2% drop in Eli Lilly’s share price and a 4% decline for Novo Nordisk. Analysts estimate a near‑term revenue loss of up to $500 million for Lilly, potentially rising to $3.3 billion if all pharmacy benefit managers (PBMs) stay out. Meanwhile, CMS extended its interim Bridge program through December 2027 to maintain limited GLP‑1 access.
Expanding the Toolkit: Non-Statin Therapies, Broader Populations, and Closing the Treatment Gap
The 2026 ACC/AHA guideline now gives strong, Class I recommendations for non‑statin therapies—bempedoic acid, PCSK9 antibodies, ezetimibe and inclisiran—for patients who cannot tolerate statins. It endorses combination regimens, such as a moderate‑intensity statin plus ezetimibe, which the RACING trial showed matches...
INBRAIN Neuroelectronics Completes Patient Recruitment for First-in-Human Study Evaluating Its Graphene Cortical Interface
INBRAIN Neuroelectronics announced that patient recruitment is complete for its first‑in‑human trial of a graphene‑based cortical interface. Ten patients were enrolled, and eight underwent surgery without any peri‑operative device failures, yielding complete datasets. The study, run with the University of...
Eye Practice and Physician Owner Agree to Pay $415,000 to Resolve Allegations of False Claims Act to Medicare
The Mitchell Eye Center and its former owner, Dr. Alan Mitchell, agreed to pay $415,000 to resolve False Claims Act allegations. U.S. authorities say the practice submitted Medicare and Veterans Health Administration claims for transcranial doppler (TCD) tests that were...
11 Key Features to Look for in Medical Practice Management Software for Healthcare Providers
Administrative tasks still consume 15%‑25% of U.S. healthcare spending—about $1 trillion annually—largely due to manual processes. The article outlines 11 essential features of modern medical practice management software that can replace paper charts, spreadsheets, and fax‑based billing with integrated digital workflows....
MSD-Backed Ray Locks in $125m to Back Eye Drug Pipeline
Ray Therapeutics announced a $125 million Series B round, led by Janus Henderson Investors with participation from Merck’s venture arm, MRL Ventures and Novo Holdings. The capital will fund late‑stage clinical work and commercial preparation for RTX‑015, its lead gene‑therapy candidate for...
Immunotherapy Offers Hope in Avoiding Bladder Removal for Cancer Patients
A new immunotherapy regimen combining checkpoint inhibitor pembrolizumab with standard chemoradiation has demonstrated a high rate of bladder preservation in patients with muscle‑invasive bladder cancer. In a multinational Phase III trial of 560 participants, 68% of patients avoided cystectomy at...
Amid US Ordeal, Moderna Wins EU Approval for Flu/COVID-19 Combo Shot
Moderna received European Commission approval for its mCOMBRIAX vaccine, a combined flu and COVID‑19 shot targeting adults 50 and older across all 27 EU members plus Iceland, Liechtenstein and Norway. The combo pairs Moderna’s next‑generation COVID vaccine mNEXSPIKE with the...
An ‘AI Scientist’ Can Tackle Drug R&D. What Does that Mean for Pharma?
AI agents are moving from analytical tools to autonomous coworkers in pharma, with Owkin’s K Pro platform acting as an “AI scientist” that can answer complex research questions in hours rather than weeks. The system pulls together literature, gene‑expression data, and...
New Data Build Case for Roche's Oral BTK Drug for MS
Roche reported that its oral BTK inhibitor fenebrutinib dramatically reduced relapse rates and MRI lesions in two phase 3 FENhance trials for relapsing multiple sclerosis, outperforming Sanofi's Aubagio. The drug cut annualised relapse rates by 51.1% and 58.5% and lowered inflammation...
Epstein-Barr Virus Methylation Aids Nasopharyngeal Cancer Screening
Researchers led by Wu, Z.C. and colleagues introduced an Epstein‑Barr virus (EBV) Cp methylation assay that triages individuals for nasopharyngeal carcinoma (NPC) risk. The method, published in Nature Communications, leverages viral DNA methylation patterns from nasopharyngeal swabs to achieve higher...
Tees, Esk and Wear Talking Therapies Improvement Challenge Highlights Steps to Improve Uptake of Digital
Tees, Esk and Wear Valleys NHS Foundation Trust completed a 100‑day improvement challenge aimed at boosting confidence among adults 65+ in using digital talking‑therapies. Over 240 seniors participated, with 96% reporting regular use of phones, tablets or laptops. Video‑based therapy...
Regeneron Reports P-III (NIMBLE) Trial Data on Cemdisiran for Generalized Myasthenia Gravis (gMG)
Regeneron presented Phase III (NIMBLE) data showing that subcutaneous cemdisiran 600 mg every 12 weeks significantly improved symptoms in adults with generalized myasthenia gravis (gMG) and anti‑AChR antibodies. Over 24 weeks, the cemdisiran arm reduced MG‑ADL scores by 4.5 points versus 2.2...
New Study Reveals CRISPR Enzyme that Responds to Human DNA Methylation
A collaborative team from Wageningen University & Research and the Van Andel Institute has identified a CRISPR-associated enzyme that senses DNA methylation, a key epigenetic mark distinguishing cancer cells from normal tissue. The enzyme selectively binds to methylated human DNA,...
Elevance Health Profits Eclipse $1.7 Billion Despite Elevated Costs
Elevance Health reported first‑quarter net income of $1.76 billion, a 17% decline from a year earlier, while total revenue rose 2.6% to $50.18 billion. The company’s benefit‑expense ratio climbed to 86.8%, reflecting higher medical costs in its Medicaid business despite modest gains...
Merck Steps up as 'Meaningful Competitor' To Gilead with HIV Pill Approval
Merck received FDA approval for Idvynso, a once‑daily, single‑pill regimen for virologically suppressed HIV‑1 adults, slated for U.S. launch on May 11, 2026. The drug demonstrated non‑inferior viral suppression versus continued Biktarvy use in two pivotal trials. Analysts see Idvynso...
Merck to Partner with Google Cloud on AI Initiatives
Merck & Co announced a partnership with Google Cloud to accelerate its artificial‑intelligence capabilities, allocating up to $1 billion over several years. The deal will fund AI infrastructure, licensing of Google’s Gemini Enterprise platform, and dedicated cloud engineers working alongside Merck...
The Deadly Reality of Eclampsia and Maternal Mortality in Nigeria
Eclampsia, a seizure‑inducing progression of pre‑eclampsia, remains a leading cause of maternal death in Nigeria, where maternal mortality exceeds 800 per 100,000 live births. Most affected women are young, first‑time mothers from rural northern communities who receive little or no...
A ‘Barbaric’ Problem in American Hospitals Is Only Getting Bigger
A personal account of a dying husband’s prolonged stays in emergency‑department (ED) boarding highlights a growing crisis in U.S. hospitals. Patients are often kept on stretchers in hallways for 24‑plus hours because inpatient beds are scarce, a problem that has...
WHO Webinar Highlights Health Sector’s Role in Boosting Parental Caregiving
The World Health Organization, together with the Child Health Task Force and the ECD Action Network, is hosting a webinar to examine how health services can embed evidence‑based parenting support from pregnancy through adolescence. Participants will review practical tools and...
FDA Approves MSD’s Once-Daily HIV Combo Idvynso
Merck’s Idvynso (doravirine/islatravir) received FDA approval, marking the first tenofovir‑free, non‑INSTI two‑drug regimen for HIV. The decision follows Phase III trials that demonstrated non‑inferior viral suppression compared with Gilead’s three‑drug standard Biktarvy. Idvynso targets virologically suppressed patients without prior treatment failure...
7 Reasons Traveling For Drug Rehab Improves Treatment Outcomes Nationwide
Traveling for drug rehabilitation acts as an environmental reset that removes patients from familiar triggers, improves detox stabilization, and boosts clinical engagement. Relocating patients enables access to specialized, evidence‑based programs and a highly structured daily routine. The broader perspective gained...
Judge Delays Purdue Pharma Sentencing, Clearing $7 B Settlement Path
U.S. District Judge Madeline Cox Arleo postponed Purdue Pharma's criminal sentencing to allow opioid victims to attend in person. The delay clears the path for a $225 million forfeiture and a $7 billion settlement from the Sackler family, which will fund government...
What to Know About the U.K.’s Generational Smoking Ban
The UK Parliament has approved the Tobacco and Vapes Bill, which will ban the sale of cigarettes, herbal smoking products and cigarette paper to anyone born in 2009 or later, creating a “smoke‑free” generation. The legislation also expands vape‑free zones...
Ipsen’s Ojemda (Tovorafenib) Receives Conditional Approval for R/R BRAF-Altered Pediatric Low-Grade Glioma (pLGG) in the EU
Ipsen’s oral kinase inhibitor Ojemda (tovorafenib) received conditional approval from the European Commission for treating pediatric low‑grade glioma (pLGG) with BRAF fusions, rearrangements or V600 mutations. The indication applies to patients six months or older who have progressed after at...
The UK Passes A Lifetime Smoking Ban. Could America Be Next?
The UK Parliament approved the Tobacco and Vapes Bill, which will permanently bar anyone born on or after Jan. 1, 2009 from purchasing tobacco, with the law taking effect on Jan. 1, 2027. The measure raises the legal smoking age by one year each...
AI Tools Let Surgeons Evaluate Heart Transplants in Minutes, Cutting Wait Times
At the ISHLT 46th Annual Meeting, Dr. Brian Wayda unveiled AI models that let surgeons gauge donor‑heart suitability in minutes. The tools, including the TOPHAT web predictor, could raise the current 30‑40% utilization rate of available hearts and ease the...
CDC Withholds Report Showing Vaccines Reduce Hospitalizations
Can't hide from science. CDC won’t publish report showing covid shots cut likelihood of hospital visits https://t.co/zajDCiaaAJ
Gene Variant, RSV Bronchiolitis Linked to Male Asthma
A new longitudinal study of 3,200 infants found that a common variant in the 17q21 locus dramatically amplifies the risk of developing asthma after early‑life respiratory syncytial virus (RSV) bronchiolitis, but only in male children. Boys carrying the risk allele...
What Leading Planned Parenthood Is Like Now
Since taking the helm in 2020, Alexis McGill Johnson has steered Planned Parenthood through a post‑Dobbs landscape marked by federal defunding, a wave of clinic closures and a shifting political spotlight. The organization, once operating over 600 health centers, has lost 53...
Can Biotech Finally Fix Infertility?
Infertility affects one in six adults worldwide, yet current care relies heavily on IVF, which still yields modest pregnancy rates—33% per transfer for standard cycles and 51% for egg donation. Biotech firms are targeting the biological gaps that IVF bypasses,...
Arkansas ACA Marketplace Enrollment Drops 12% as Subsidies Expire
Effective April 15, Arkansas enrollment in the ACA marketplace slipped to 134,310, a 12% decline from a year earlier, following the end of the federal enhanced premium tax credits. The drop is steeper in rural counties and coincides with premium...
Expanded HSA Eligibility Creates Need for Employee Education: 4 Critical Tips
Recent legislation expands Health Savings Account eligibility to bronze and silver Affordable Care Act plans, opening HSA participation to a broader employee base. Employers can now tap this tax‑advantaged tool to help workers manage current medical costs and build retirement...
Ractigen Therapeutics Shows 81% NfL Drop in Phase I ALS Trial
Ractigen Therapeutics announced that a single intrathecal dose of its siRNA drug RAG-17 cut plasma neurofilament light chain by 81% in a Phase I study of SOD1‑ALS patients, while showing a clean safety profile. The data, presented at the 2026...
Bristol NHS Group Opens Doors to Tech Providers to Inspire Staff, in Flagship Elevate Showcase
Bristol NHS Group is hosting the Elevate Local Health Tech Showcase on 13 May, inviting health‑social care staff from its two trusts and the wider integrated care system to meet technology suppliers. The event, part of the group’s new digital strategy...
Robotic Phlebotomy Study Signals Automation Shift for Clinical Labs
Vitestro’s autonomous robotic phlebotomy system Aletta completed a multicenter ADOPT trial involving 1,633 patients, achieving a 94.5% first‑stick success rate and markedly low hemolysis (0.3%) and adverse events (0.6%). Patient surveys showed 90% experienced equal or less pain, with 82%...
How Compounding Has Become a Permanent Bridge for Healthcare Access: Q&A with Dr. Nicole Snow
Compounding pharmacies are positioning themselves as a permanent bridge to healthcare access by delivering highly individualized therapies when commercial products fall short. Dr. Nicole Snow of Wesley Pharmaceuticals explains how custom dosing, alternative dosage forms, and allergen‑free excipients close care...
Top Drugs at Risk of Supply Shortages: Report
The U.S. Pharmacopeia’s new vulnerable medicines report flags 100 drugs—half of which depend on a single‑country key starting material—as prone to supply shocks. While only 30 of these are in active FDA shortage, the list highlights injectables, ICU sedatives, IV...
Rapid Blood Infection Test Fails to Improve Survival
A large, open‑label randomized trial of 899 patients with gram‑negative bacteremia compared rapid antimicrobial susceptibility testing directly from positive blood cultures to standard sub‑culture testing. The rapid approach delivered susceptibility results in about 7.5 hours versus 44 hours for the conventional method,...
New Nanomedicine Approach Boosts Chemotherapy And Immune Activity In Pancreatic Cancer
A preclinical mouse study published in Advanced Science demonstrates that photoactivatable multi‑inhibitor liposomes (PMILs) can deliver irinotecan directly to pancreatic ductal adenocarcinoma (PDAC) tumors when activated by light. The regimen combines minocycline‑mediated DNA‑repair inhibition, photodynamic priming, and localized chemotherapy, boosting...
CovAngelo Accurately Models Reaction Barriers for Covalent Drug Discovery
BEIT introduced CovAngelo, a layered QM/QM/MM platform that accurately predicts activation barriers for covalent inhibitors. By combining classical molecular mechanics, quantum‑mechanical embedding (ECC‑DMET), and high‑level quantum chemistry focused on the bond‑forming event, the method captures subtle electronic and environmental effects...
Will Your Retirement Income Trigger the IRMAA This Year? (Plus, 6 Ways to Avoid It in the Future)
The article explains how the income‑related monthly adjustment amount (IRMAA) raises Medicare Part B and D premiums for retirees whose 2024 modified adjusted gross income (MAGI) exceeds $108,000 for single filers or $218,000 for married couples. Even a single dollar over...
The Great Unbalding. Fallen Follicles, Rise! (NY Mag)
Scientists at Pelage Pharmaceuticals unveiled PP405, a novel drug that reprograms dormant hair‑follicle stem cells to regrow thick hair on balding scalp. Early Phase 2a data released in June 2024 showed rapid regrowth in areas previously considered irreversibly lost, sparking intense...
New Study Published Evaluating PharmaSens All-in-One Insulin Patch Pump
PharmaSens AG announced that the Journal of Diabetes Science and Technology published data from the first clinical feasibility study of its niia all‑in‑one insulin patch pump, which combines insulin delivery with continuous glucose monitoring. The single‑arm trial enrolled 18 adults...
BioAegis and Prenosis Partner for Inflammatory Disease Therapies
BioAegis Therapeutics has teamed up with AI‑focused startup Prenosis to accelerate precision‑medicine approaches for inflammatory diseases. The partnership will analyze biospecimens from BioAegis’s Phase II BTI‑203 trial of recombinant human plasma gelsolin in 600 ARDS patients across Europe, Canada and the...
Why Advisers Must Move From 'Retailers' To 'Guardians'
U.S. commercial healthcare consumes about $1.3 trillion annually, with roughly $325 billion—equivalent to a $4,000 per‑employee leak—attributed to administrative waste and opaque PBM pricing. Traditional benefits brokers earn commissions tied to premium volume, creating a direct conflict between adviser income and client...
Medicare Obesity Drug Pilot Extended After Insurer Pushback
The Trump administration has pushed back the start of the Medicare GLP‑1 Bridge pilot by a year after insurers fell short of the 80% enrollment target. The federal government will continue to cover drugs such as Novo Nordisk’s Wegovy, Eli Lilly’s...
Belief in Treatment Lowers Brain Pain Activity
Simply believing you’re being treated can measurably reduce the brain’s pain processing. MRI scans across 20 studies show that placebo treatment reduces activity in pain-processing brain regions. The effect is small, but consistent. Full video on placebo: https://t.co/l1PV2LNyhA Study: PMID: 33654105
Planning AHPRA Registration? English Requirements Change From 23 April 2026
AHPRA will tighten English language standards for registration starting 23 April 2026. While overall IELTS/PEL scores and the Listening and Reading components are being lowered, the Speaking component is being raised across all accepted tests. Applicants must now demonstrate stronger oral communication...
4 Medications That May Increase Dementia Risk
Recent health reports highlight that certain over‑the‑counter and prescription drugs, especially anticholinergic antihistamines, may raise dementia risk by about 50 percent. While medications like statins and some blood‑pressure treatments appear protective, the evidence linking anticholinergics to cognitive decline stems mainly...